(Q33528163)

27 July 2017

title

Stereotactic body radiotherapy for organ-confined prostate cancer (English)

1 reference

adaptive radiation therapy

27 July 2017

main subject

0 references

1 reference

Alan J Katz

1

1 reference

27 July 2017

Michael Santoro

2

1 reference

27 July 2017

Richard Ashley

3

1 reference

27 July 2017

Ferdinand Diblasio

4

1 reference

27 July 2017

Matthew Witten

5

1 reference

27 July 2017

publication date

1 February 2010

1 reference

27 July 2017

1 reference

27 July 2017

volume

10

1 reference

27 July 2017

page(s)

1

1 reference

Creative Commons Attribution 2.0 Generic

27 July 2017

copyright license

start time

1 February 2010

1 reference

April 2022 Public Data File from Crossref

copyright status

copyrighted

1 reference

April 2022 Public Data File from Crossref

cites work

Intrarectal amifostine during external beam radiation therapy for prostate cancer produces significant improvements in Quality of Life measured by EPIC score

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2831888

Is the alpha/beta value for prostate tumours low enough to be safely used in clinical trials?

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2831888

Image-guided radiosurgical ablation of intra- and extra-cranial lesions

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2831888

Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2831888

High-dose-rate intensity-modulated brachytherapy with external beam radiotherapy for prostate cancer: California endocurietherapy's 10-year results

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2831888

Acute and late complications after radiotherapy for prostate cancer: results of a multicenter randomized trial comparing 68 Gy to 78 Gy.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2831888

Meta-analysis of rates of erectile function after treatment of localized prostate carcinoma

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2831888

Health outcomes after prostatectomy or radiotherapy for prostate cancer: results from the Prostate Cancer Outcomes Study.

21 June 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2490-10-1

Hypofractionated versus conventionally fractionated radiation therapy for prostate carcinoma: updated results of a phase III randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2490-10-1

Hypofractionated conformal radiotherapy in carcinoma of the prostate: five-year outcome analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2490-10-1

Conformal high dose rate brachytherapy improves biochemical control and cause specific survival in patients with prostate cancer and poor prognostic factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2490-10-1

Stereotactic hypofractionated accurate radiotherapy of the prostate (SHARP), 33.5 Gy in five fractions for localized disease: first clinical trial results

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2490-10-1

Stereotactic body radiotherapy for localized prostate cancer: interim results of a prospective phase II clinical trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2490-10-1

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2490-10-1

Development and validation of the expanded prostate cancer index composite (EPIC) for comprehensive assessment of health-related quality of life in men with prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2490-10-1

Comparison of conventional-dose vs high-dose conformal radiation therapy in clinically localized adenocarcinoma of the prostate: a randomized controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2490-10-1

Protective effect of amifostine during fractionated radiotherapy in patients with pelvic carcinomas: results of a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2490-10-1

Hypogonadism following prostate-bed radiation therapy for prostate carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2490-10-1

Radiotherapy for rectal cancer is associated with reduced serum testosterone and increased FSH and LH.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2490-10-1

Testicular dose from prostate cyberknife: a cautionary note

21 January 2018

1 reference

12 December 2020

Screening for prostate cancer: U.S. Preventive Services Task Force recommendation statement

1 reference

12 December 2020

Time of decline in sexual function after external beam radiotherapy for prostate cancer

1 reference

12 December 2020

Radical external beam radiotherapy for localised carcinoma of the prostate using a hypofractionation technique

1 reference

12 December 2020

The GETUG 70 Gy vs. 80 Gy randomized trial for localized prostate cancer: feasibility and acute toxicity

1 reference

12 December 2020

Toxicity after three-dimensional radiotherapy for prostate cancer on RTOG 9406 dose Level V

1 reference

12 December 2020

Randomized Trial Comparing Two Fractionation Schedules for Patients With Localized Prostate Cancer

1 reference

12 December 2020

Hypofractionated intensity-modulated radiotherapy (70 Gy at 2.5 Gy per fraction) for localized prostate cancer: Cleveland Clinic experience

1 reference

12 December 2020

Patterns of toxicity following high-dose-rate brachytherapy boost for prostate cancer: mature prospective phase I/II study results

1 reference

12 December 2020

Long-Term Results of the M. D. Anderson Randomized Dose-Escalation Trial for Prostate Cancer

1 reference

12 December 2020

Quality of life and satisfaction with outcome among prostate-cancer survivors

1 reference

12 December 2020

Identifiers

DOI

10.1186/1471-2490-10-1

1 reference

Dimensions Publication ID

27 July 2017

1 reference

https://scigraph.springernature.com/pub.10.1186/1471-2490-10-1

9 September 2019

1 reference

27 July 2017

1 reference